BACKGROUND: A common polymorphism of the beta(1)-adrenergic receptor Arg389Gly markedly affects function in vitro, but little is known about its in vivo significance. METHODS AND RESULTS: Resting and exercise hemodynamic responses were measured in subjects homozygous for Arg389 (n = 21) or Gly389 (n = 13) alleles before and 3 hours after administration of a beta-blocker, atenolol. Demographic characteristics and atenolol concentrations were similar in the two genotypic groups. Genotype had a marked effect on resting hemodynamic responses to atenolol, with Arg389-homozygous subjects having a larger decrease in resting systolic blood pressure (8.7 +/- 1.3 mm Hg versus 0.2 +/- 1.7 mm Hg, P < .001) and mean arterial blood pressure (7.2 +/- 1.0 mm Hg versus 2.0 +/- 1.7 mm Hg, P = .009). Attenuation of exercise-induced hemodynamic responses by atenolol was not affected by genotype. CONCLUSIONS: There is reduced sensitivity of Gly389 homozygotes to a beta-adrenergic receptor antagonist, and this polymorphism may be an important determinant of variability in response to beta-blockade.
BACKGROUND: A common polymorphism of the beta(1)-adrenergic receptor Arg389Gly markedly affects function in vitro, but little is known about its in vivo significance. METHODS AND RESULTS: Resting and exercise hemodynamic responses were measured in subjects homozygous for Arg389 (n = 21) or Gly389 (n = 13) alleles before and 3 hours after administration of a beta-blocker, atenolol. Demographic characteristics and atenolol concentrations were similar in the two genotypic groups. Genotype had a marked effect on resting hemodynamic responses to atenolol, with Arg389-homozygous subjects having a larger decrease in resting systolic blood pressure (8.7 +/- 1.3 mm Hg versus 0.2 +/- 1.7 mm Hg, P < .001) and mean arterial blood pressure (7.2 +/- 1.0 mm Hg versus 2.0 +/- 1.7 mm Hg, P = .009). Attenuation of exercise-induced hemodynamic responses by atenolol was not affected by genotype. CONCLUSIONS: There is reduced sensitivity of Gly389 homozygotes to a beta-adrenergic receptor antagonist, and this polymorphism may be an important determinant of variability in response to beta-blockade.
Authors: Utkarsh Kohli; André Diedrich; Prince J Kannankeril; Mordechai Muszkat; Gbenga G Sofowora; Maureen K Hahn; Brett A English; Randy D Blakely; C Michael Stein; Daniel Kurnik Journal: Physiol Genomics Date: 2015-06-09 Impact factor: 3.107
Authors: Janina M Jeff; Brian S Donahue; Kristin Brown-Gentry; Dan M Roden; Dana C Crawford; C Michael Stein; Daniel Kurnik Journal: Am Heart J Date: 2013-10-17 Impact factor: 4.749
Authors: Amy L Pasternak; Kristen M Ward; Jasmine A Luzum; Vicki L Ellingrod; Daniel L Hertz Journal: Physiol Genomics Date: 2017-09-08 Impact factor: 3.107
Authors: Steven M Swift; Brigitte R Gaume; Kersten M Small; Bruce J Aronow; Stephen B Liggett Journal: Physiol Genomics Date: 2008-07-29 Impact factor: 3.107
Authors: Daniel Kurnik; Andrew J Cunningham; Gbenga G Sofowora; Utkarsh Kohli; Chun Li; Eitan A Friedman; Mordechai Muszkat; Usha B Menon; Alastair Jj Wood; C Michael Stein Journal: Pharmacogenomics Date: 2009-10 Impact factor: 2.533